Clin2
NCT07190196Possibly a fitRecruiting

Study of Rilzabrutinib for IgG4-related disease

Immunoglobulin G4 Related Disease

Treatments studied

Part of Immune system & allergy clinical trials.

This trial tests a medication called rilzabrutinib to see if it can safely control IgG4-related disease (a condition causing inflammation in various organs) better than a placebo. It may help you reduce or stop your current steroid treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
124 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have been diagnosed with active IgG4-related disease by a special committee.
  • Your disease must be active in at least one organ (like the pancreas, kidneys, or salivary glands) within the last month.
  • You must be taking a stable dose of steroids for at least 2 weeks and be willing to slowly stop them during the study.
  • You cannot have certain other conditions like retroperitoneal fibrosis (scarring in the abdomen) or a history of cancer in the last 5 years.
  • You must be up to date on your vaccines, and cannot have had a live vaccine within 30 days of starting the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07222553Not yet recruiting· Phase 2
Testing inebilizumab for children with IgG4-related disease

This trial tests if inebilizumab is safe and works well for children with IgG4-related disease (a condition causing swelling in various organs). It may be an option if your child needs treatment beyond steroids.

Tampa, Florida
NCT07719543Not yet recruiting· Phase 3
Lenalidomide to prevent IgG4-related disease relapse

This trial tests if lenalidomide, taken as a pill, can help prevent IgG4-related disease from coming back (relapsing) in people who are already in remission on low-dose steroids.

Beijing, Beijing Municipality
NCT06270524Not yet recruiting
C5a/C5aR1 study in IgG4-related disease

This study looks at a specific immune signal (C5a/C5aR1) in IgG4-related disease to see if blocking that signal could be a future treatment. It compares blood samples from people with active disease, people in remission, and healthy volunteers.

NCT07621939Not yet recruiting· Phase 2/Phase 3
IMM0306 Treatment for IgG4-Related Disease

This trial tests a new medicine called IMM0306 for IgG4-related disease, a condition where the immune system attacks multiple organs in your body. The study aims to see if IMM0306 can help control your disease and reduce flare-ups while using less steroid medication.

NCT06984627Recruiting· Phase 2
Study of Rilzabrutinib for Adults with Graves' Disease

This study tests an experimental pill called rilzabrutinib for people with Graves' disease, a condition where the immune system attacks the thyroid. It aims to see if the drug can help control the overactive thyroid and any related eye problems.

Calgary, Alberta
NCT07061938Recruiting· Phase 1/Phase 2
Study of ACE1831 for active IgG4-related disease

This trial tests a new drug called ACE1831 for people with active IgG4-related disease that affects more than one organ. It aims to see if the drug can safely control the disease and reduce the need for steroids.

Atlanta, Georgia

Hear when a new Immunoglobulin G4-Related Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.